(5-amino-3-phenyl-1,2,4-triazol-1-yl)-(2-methoxyphenyl)methanone is a complex organic molecule. Its importance for research lies in its potential applications in various fields, particularly in:
**1. Medicinal Chemistry and Drug Discovery:**
* **Anti-cancer activity:** The compound has shown promising activity against various cancer cell lines in pre-clinical studies. It is being investigated for its potential as a new anti-cancer agent.
* **Anti-microbial activity:** Research suggests it may have potential as an anti-microbial agent, particularly against bacterial infections.
* **Other therapeutic applications:** Its unique chemical structure makes it a potential candidate for developing drugs against various diseases, including inflammatory conditions, autoimmune disorders, and neurological diseases.
**2. Material Science:**
* **Luminescent properties:** The compound exhibits fluorescence, making it a potential candidate for use in organic light-emitting diodes (OLEDs) and other optical materials.
* **Non-linear optical properties:** Its structure might possess properties that make it useful in developing novel optical materials for applications in telecommunications and data storage.
**3. Synthetic Chemistry:**
* **Building block for new molecules:** The unique structure of (5-amino-3-phenyl-1,2,4-triazol-1-yl)-(2-methoxyphenyl)methanone makes it a valuable building block for synthesizing new organic molecules with desired properties.
**Research is ongoing to fully understand the potential of this compound and to explore its applications in different fields.**
**Note:** It is important to remember that the information provided is based on existing scientific literature. Further research is necessary to confirm the specific applications and potential of this molecule.
ID Source | ID |
---|---|
PubMed CID | 895500 |
CHEMBL ID | 1559553 |
CHEBI ID | 107499 |
SCHEMBL ID | 2572748 |
Synonym |
---|
smr000074078 |
MLS000099470 , |
1-(2-methoxybenzoyl)-3-phenyl-1h-1,2,4-triazol-5-amine |
CHEBI:107499 |
mfcd04212084 |
AKOS004928502 |
(5-amino-3-phenyl-1,2,4-triazol-1-yl)-(2-methoxyphenyl)methanone |
HMS2159M22 |
HMS3314E07 |
CHEMBL1559553 |
cid_895500 |
(5-azanyl-3-phenyl-1,2,4-triazol-1-yl)-(2-methoxyphenyl)methanone |
bdbm45404 |
SCHEMBL2572748 |
Q27185820 |
VU0047562-1 |
sr-01000268012 |
SR-01000268012-1 |
Class | Description |
---|---|
triazoles | An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 19.9526 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 25.1189 | 0.0251 | 20.2376 | 39.8107 | AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 25.1189 | 0.0251 | 20.2376 | 39.8107 | AID893 |
15-lipoxygenase, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0126 | 10.6917 | 88.5700 | AID887 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 3.5481 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 7.9433 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 1.7783 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Coagulation factor XII | Homo sapiens (human) | IC50 (µMol) | 2.2413 | 0.0104 | 3.8890 | 10.9666 | AID852 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
serine-type endopeptidase activity | Coagulation factor XII | Homo sapiens (human) |
calcium ion binding | Coagulation factor XII | Homo sapiens (human) |
protein binding | Coagulation factor XII | Homo sapiens (human) |
misfolded protein binding | Coagulation factor XII | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
extracellular region | Coagulation factor XII | Homo sapiens (human) |
extracellular space | Coagulation factor XII | Homo sapiens (human) |
plasma membrane | Coagulation factor XII | Homo sapiens (human) |
collagen-containing extracellular matrix | Coagulation factor XII | Homo sapiens (human) |
extracellular exosome | Coagulation factor XII | Homo sapiens (human) |
extracellular space | Coagulation factor XII | Homo sapiens (human) |
rough endoplasmic reticulum | Coagulation factor XII | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |